EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Modified vs Full Lead-in Dose Apixaban and Rivaroxaban for Treatment of Acute Venous Thromboembolism

Jeanette Lahoud iD, Josephine Jacobs, Lauren Ratrut, Amanda Kitten, Crystal Franco-Martinez

Annals of Pharmacotherapy · 28.06.2026

DOI: 10.1177/10600280261456308 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 28.06.2026. Verfasst von Jeanette Lahoud und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy and Pharmacy Services, University Health, San Antonio, TX, USA. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Apixaban and rivaroxaban, direct oral anticoagulants (DOACs) used for acute venous thromboembolism (VTE) treatment, require higher dose lead-in periods of 7 days and 21 days, respectively. The optimal lead-in duration for patients receiving more than 48 hours of parenteral anticoagulation (AC) is unclear. In addition, guidelines lack recommendations for high bleed-risk patients who might benefit from a shortened lead-in.

Objective

This study aimed to evaluate the effectiveness and safety of a modified lead-in strategy, where parenteral AC counts toward shortening or eliminating the DOAC lead-in period, compared to a full lead-in strategy, where a 7-day apixaban or 21-day rivaroxaban lead-in is prescribed irrespective of parenteral AC received.

Methods

A retrospective cohort study analyzed patients diagnosed with an acute VTE during hospitalization. Patients were grouped based on a modified versus full lead-in strategy. Primary outcomes of recurrent VTE (rVTE) and bleeding were evaluated at 90 days.

Results

Of 101 included patients, 47 were in the modified lead-in group and 54 in the full lead-in group. Patients in the modified lead-in group had a higher risk of bleeding at baseline. Recurrent VTE occurred in 4 patients in the modified lead-in group, compared to 2 patients in the full lead-in group (9% vs 4%; P = .4129). Bleeding occurred in 10 patients in the modified lead-in group, compared to 3 patients in the full lead-in group (21% vs 6%; P = .0167). Conclusion and Relevance: No significant difference in rVTE was observed between groups. The modified lead-in group had a higher incidence of bleeding, possibly reflecting greater baseline risk and clinical complexity rather than the modification itself. Modified lead-in strategies may be reasonable in select patients, particularly those at high risk for bleeding; however, larger studies are needed to confirm safety and efficacy.

Schlagwörter

Stichwörter der Autor:innen

anticoagulationbleedingclinical practicedirect oral anticoagulantsthromboembolic diseases

Autor:innen und Institutionen

  • Department of Pharmacotherapy and Pharmacy Services, University Health, San Antonio, TX, USA.
  • Department of Pharmacy Practice, Feik School of Pharmacy, University of the Incarnate Word, San Antonio, TX, USA.
  • The University of Texas Health Science Center at San Antonio, USA.

ORCID-Profile: Jeanette Lahoud

Zitieren

APA

Lahoud, J., Jacobs, J., Ratrut, L., Kitten, A., & Franco-Martinez, C. (2026). Modified vs Full Lead-in Dose Apixaban and Rivaroxaban for Treatment of Acute Venous Thromboembolism. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280261456308

Vancouver

Lahoud J, Jacobs J, Ratrut L, Kitten A, Franco-Martinez C. Modified vs Full Lead-in Dose Apixaban and Rivaroxaban for Treatment of Acute Venous Thromboembolism. Annals of Pharmacotherapy. 2026. doi:10.1177/10600280261456308

BibTeX
@article{Lahoud2026,
  author = {Lahoud, Jeanette and Jacobs, Josephine and Ratrut, Lauren and Kitten, Amanda and Franco-Martinez, Crystal},
  title = {Modified vs Full Lead-in Dose Apixaban and Rivaroxaban for Treatment of Acute Venous Thromboembolism},
  journal = {Annals of Pharmacotherapy},
  year = {2026},
  doi = {10.1177/10600280261456308}
}
Kostenlos starten →